Drugs.com New Drug ApprovalsOriginal article
Octapharma USA Announces Expanded FDA Approval of Wilate for von Willebrand Disease Prophylaxis in Children Younger Than 6 Years
RegulatoryapprovedWilatePositive
AI Analysis
Summary
Octapharma USA announced FDA approval on July 2, 2026 of Wilate for routine prophylaxis to reduce the frequency of von Willebrand disease in children younger than 6 years, representing an expanded indication for the von Willebrand Factor/Coagulation Factor VIII Complex therapy.
Outcome Details
FDA approved expanded indication for Wilate for routine prophylaxis in children younger than 6 years with von Willebrand disease
Importance:7/10
Sentiment:
0.85
FDA approvalexpanded indicationpediatricvon Willebrand diseaseprophylaxis
Read the original article
Published by Drugs.com New Drug Approvals on July 8, 2026 12:07 AM